The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
Rebecca Newton(University of Manchester), Donald Ogilvie(Bioscience Research), Laura A. Maguire(University of Manchester), Daniel P. Mould(University of Manchester), Neil Q. McDonald(The Francis Crick Institute), Amanda Lyons(University of Manchester), H. Nikki March(University of Manchester), Gemma V. Hopkins(University of Manchester), Sarah V. Holt(Pharma Nord (United Kingdom)), Katherine A. Bowler(University of Manchester), Bohdan Waszkowycz(University of Manchester), Samantha Fritzl(University of Manchester), Andrew G. Purkiss(Cancer Research UK), Alexandra Stowell(University of Manchester), Emily M. Burns(Cancer Research UK), Allan M. Jordan(Signature Research (United States)), Ian D. Waddell(Charles River Laboratories (United Kingdom)), Emma Fairweather(University of Manchester), Kristin Goldberg(University of Manchester), P Chapman(University of Manchester), Stuart Jones(University of Manchester), Graeme Thomson(University of Manchester), Niall M. Hamilton(Ninewells Hospital), Amanda J. Watson(University of Manchester), Helen Small(University of Manchester)
Cited by 40
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
New protein fold revealed by a 2.3-Å resolution crystal structure of nerve growth factor
|Nature|1991|500
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344